Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

NewsGuard 100/100 Score

Sinovac Biotech Ltd. ( SVA), a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

Parenteral intends to apply to the Drug Controller General of India (DCGI) for the import approval for the vaccines. The volume, delivery schedule and other specific details about how Sinovac's vaccines may be marketed and supplied to the government of India and the private market in India have not been determined.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, stated, "The agreements correspond with Sinovac's international marketing strategy to partner with established local suppliers to secure regulatory approval and more efficiently facilitate distribution in numerous international markets. We look forward to partnering with Parenteral Biotech to bring our seasonal influenza vaccine and H1N1 vaccine to the people of India."

Source:

Sinovac Biotech Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The path to a better tuberculosis vaccine runs through Montana